Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23608933 | 0.86 | HSP90AA1 (0.31) | HSP90AA1NPSR1CYP3A4THRBALDH1A1 | |
| SCHEMBL23876037 | 0.84 | HSP90AA1 (0.31) | HSP90AA1NPSR1CYP3A4THRB | |
| SCHEMBL23609146 | 0.84 | HSP90AA1 (0.33) | HSP90AA1NPSR1CYP3A4THRBKMT2A | |
| SCHEMBL23609212 | 0.82 | HSP90AA1 (0.37) | HSP90AA1NPSR1CYP3A4THRBALDH1A1 | |
| SCHEMBL23876086 | 0.79 | EGLN3 (0.33) | HSP90AA1NPSR1CYP3A4THRBALDH1A1 | |
| SCHEMBL10204805 | 0.72 | MEN1 (0.35) | ALDH1A1MAPTKMT2A | |
| SCHEMBL23608952 | 0.71 | PDE5A (0.36) | HSP90AA1NPSR1CYP3A4ALDH1A1CYP2C9 | |
| SCHEMBL30405860 | 0.70 | CYP2D6 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL6632043 | 0.69 | HSP90AA1 (0.39) | HSP90AA1NPSR1CYP3A4THRBALDH1A1 | |
| SCHEMBL30406534 | 0.69 | PDE3B (0.34) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2021195346-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | HSP90AA1 2483/4885NPSR1 2470/4885CYP3A4 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.